The molecules include novel imaging and radiotherapeutic agents for Epstein Barr Virus (EBV) associated tumors and prostate cancer. The EBV technology, published in the October 2008 issue of the journal Nature Medicine, leverages a specific enzyme produced by the virus to allow for the imaging and therapy of the tumors caused by the virus, which include numerous lymphomas, stomach cancer, nasopharyngeal cancers, and most AIDS related lymphomas.
As per the terms of the agreement, the license gives Principio exclusive, worldwide rights to commercialise imaging agents and therapy.
Joe Hernandez, founder and CEO of Principio, said: “We are extremely delighted to have obtained exclusive rights to these novel, revolutionary, and much needed imaging and radiotherapeutic molecules. We will move quickly to commercialise these much needed therapies for these devastating cancers.”